Moscow, December 30, 2020 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and the Health Supply Centre (Central de Abastecimiento y Suministros de Salud, CEASS) of the Plurinational State of Bolivia announce the agreement to supply the country with 2.6 million doses of Sputnik V, the world’s first registered vaccine against coronavirus.
The signing ceremony took place in a video-conference format today and the Constitutional President of the Plurinational State of Bolivia, Luis Alberto Arce Catacora, Vice President David Choquehuanca Céspedes, the Minister of Health and Sports of Bolivia, Edgar Pozo Valdivia, General Director of the CEASS, Victor Hugo Aguilar Frias, Deputy Director of the Latin American Department of the Ministry of Foreign Affairs of Russia, Vladimir Belinskiy, and the CEO of the Russian Direct Investment Fund, Kirill Dmitriev, were in attendance.
The agreement will make it possible for more than 20% of Bolivia’s population to access the vaccine. Supply of the vaccine will be facilitated by RDIF’s international partners in India, China, South Korea and other countries.
The efficacy of the vaccine is 91.4% according to the results of the third and final control point analysis of Russian Phase III clinical trials data obtained 21 days after administering the first dose to volunteers. Calculation was based on the analysis of data of volunteers (n = 22 714) who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol. The vaccine demonstrated 100% efficacy against severe coronavirus cases.
The Sputnik V coronavirus vaccine Gamaleya Center has a unique set of parameters, making it one of the most competitive vaccines globally. With an efficacy rate of over 90%, the vaccine is based on a reliable, safe and well-researched human adenoviral vector platform. The cost of one dose is less than $10 for international markets and the production of the lyophilized (dry) form of the vaccine, which is stored at a temperature of +2 to +8 degrees Celsius, enables the vaccine to be easily distributed to international markets.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Russia is actively developing cooperation with Bolivia in the fight against the novel coronavirus infection. We would like to express our gratitude to President Luis Alberto Arce Catacora for trusting the Sputnik V vaccine. The Russian vaccine is based on a well-researched human adenoviral vector platform which has proven to be safe, with no long-term adverse effects in more than 250 clinical trials over decades.
Earlier this year, the first Russian anti-COVID drug, Avifavir, was delivered to Bolivia, and we are pleased to open a new chapter in our joint efforts to overcome the pandemic. The safe and highly effective Sputnik V vaccine will protect more than 20% of Bolivia's population. We look forward to widening our cooperation on the vaccine with other Latin American countries in the future”.
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: [email protected]
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133
Message has been successfully sent!